α-Galactosidase A catalyzes the hydrolysis of substrates possessing terminal α-galactosidic residues, including synthesis substrates and naturally occurring GSLs and glycoproteins. The molecular weight of the native enzyme from human tissue is approximately 103 000 with a homo- or hetero-dimeric structure [495].
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Alpha-Galactosidase A
Drug Overview
What is Alpha-Galactosidase A?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Alpha-Galactosidase A is a lysosomal enzyme that breaks down certain glycosphingolipids, such as globotriaosylceramide. A deficiency of this enzyme causes Fabry disease, and recombinant forms are used as enzyme replacement therapy. Its assessment considers the specific properties of protein therapeutics, including potency, immunogenicity and handling risks during manufacturing.
A PDE or ADE sets a health-based limit on daily exposure to Alpha-Galactosidase A from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Yes. Although large molecules can differ from small molecules in absorption and stability, peptides and proteins may still have potent pharmacological effects. A PDE supports cross-contamination control in shared facilities, while an OEL helps protect workers who may be exposed to Alpha-Galactosidase A through inhalation or skin contact during manufacturing.
An assessment should be reviewed when new toxicological or clinical data become available, when the way the substance is used or handled changes, or when relevant regulatory guidance is updated. Periodic review keeps the limits for Alpha-Galactosidase A aligned with current evidence and helps ensure that containment and cleaning decisions remain scientifically justified.
A PDE, or permitted daily exposure, addresses patient safety by limiting how much of Alpha-Galactosidase A may be carried over into another medicinal product each day. An OEL, or occupational exposure limit, addresses worker safety by limiting airborne concentrations in the workplace. Both draw on the same toxicological evidence but serve different purposes and use different assumptions.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Alpha-Galactosidase A in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
For biologics and peptides, the intended pharmacological effect is often the most sensitive endpoint. The assessment of Alpha-Galactosidase A considers its mechanism, the lowest doses that produce a clinical or pharmacodynamic effect and any immunological effects. These factors help identify the critical effect and determine how conservative the resulting health-based limits need to be.
Not always. An OEB places Alpha-Galactosidase A in a hazard band and is especially useful early in development or when data are limited. A specific OEL, where one can be derived, gives a more precise benchmark for exposure monitoring. Many organizations use the band to guide containment and the OEL to verify that controls are working as intended.
Uncertainty factors account for differences between test species and humans, variability between individuals, study duration and quality, and gaps in the available data. Each factor must be scientifically justified and documented so reviewers can follow how the final health-based limit was reached.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Alpha-Galactosidase A to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
